-
Drug-Induced Liver Injury Warning Added To OFEV Label In Canada As Done Earlier In US
This Relatively New Idiopathic Pulmonary Fibrosis (IPF) Pill Is Clearly On The Radar Of Drug Safety Regulators (Posted by Tom Lamb at DrugInjuryWatch.com) OFEV (nintedanib) capsules were approved by the FDA in 2014…
-
Drug Injury Watch: 2017 Collection Of Articles / Blog Posts
Written by: Heather Helmendach, Legal Assistant Law Offices of Thomas J. Lamb, P.A. At the Law Offices of Thomas J. Lamb, we are committed to providing up-to-date information on matters pertaining to drug…
-
Gadolinium-Containing Contrast Agents Omniscan And Magnevist Being Recalled In The United Kingdom In February 2018
In Comparison, This December 2017 Regulatory Action By FDA In The US: “new class warning… for all gadolinium-based contrast agents” (Posted by Tom Lamb at DrugInjuryWatch.com) There seems to be a consensus…
-
FDA Recommends A Recall For Limbrel “Medical Food” Product But Primus Pharmaceuticals Is Not Complying
Reports Of Drug-Induced Liver Injury And Hypersensitivity Pneumonitis Are At Center Of This Unusual Drug Safety Controversy (Posted by Tom Lamb at DrugInjuryWatch.com) UPDATE: Primus Pharmaceuticals Inc. Finally Removes Its Osteoarthritis Capsule Limbrel…
-
Jardiance – Amputations Drug Safety Issue Remains Uncertain Due To Admitted “inherent limitations of… post hoc analyses”
Jardiance Seemingly Not Associated With Amputations Per Reexamination Of Drug Company Funded EMPA-REG OUTCOME® Trial Data (Posted by Tom Lamb at DrugInjuryWatch.com) In April 2016 the European Medicines Agency (EMA) warned that…
-
New Heart Failure Drug Entresto Apparently Has Safety Signal For Hypotension (Low Blood Pressure) Side Effect
Will Recent ISMP QuarterWatch Report Prompt FDA Regulatory Action, Including Possible Drug Label Change By Novartis? (Posted by Tom Lamb at DrugInjuryWatch.com) The FDA approved Entresto™ (sacubitril and valsartan) tablets in July…